title: Local and global returns from research in stem cells: the case of the California Institute for Regenerative Medicine.
abstract: As of July 2010, the California Institute for Regenerative Medicine (CA, USA) had awarded US$1.1 billion to over 50 institutions which obtained $884.3 million in matching funds. Those grants have one-time and ongoing economic impacts: the former during the disbursement of the funds locally, while the latter result from structural changes and are global. For the period 2006-2014, one-time impacts in California (USA) are 24,000 jobs/year and $201 million in tax revenues for California ($362 million for the federal government). A grantee developed an inhibitor to treat polycythemia vera and primary myelofibrosis. The patients in remission who will return to work will cause an average increase of $94.4 million in California's annual personal income ($560.9 million for the USA) and tax revenues of $46.7 million over 10 years. The annual decrease in direct healthcare costs in California is $2.1 million. Grantees concentrate in two clusters--San Francisco and San Diego--strengthening California's leadership in stem cell research.
authors: Berkeley Research Group, LLC, Emeryville, CA 94608, USA. jalberro@brg-expert.com
authors: José
authors: J
authors: Alberro
mesh_terms: D000047:Academies and Institutes / Q000191:economics*; D002140:California; D005381:Financing, Organized; D006801:Humans; D011087:Polycythemia Vera / Q000191:economics / Q000628:therapy; D055728:Primary Myelofibrosis / Q000191:economics / Q000628:therapy; D044968:Regenerative Medicine / Q000191:economics*; D057905:Stem Cell Research / Q000191:economics*; D013660:Taxes / Q000191:economics*